<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838548</url>
  </required_header>
  <id_info>
    <org_study_id>MRG003-002</org_study_id>
    <nct_id>NCT04838548</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>An Open-Label, Multi-Cohort, Multi-center, Non-Randomized, Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Miracogen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Miracogen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy, safety of MRG003 as single agent in&#xD;
      EGFR-positive advanced non-small cell lung cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) by Investigator</measure>
    <time_frame>Baseline to study completion, up to 12 months</time_frame>
    <description>ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to study completion, up to 12 months</time_frame>
    <description>PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline to study completion, up to 12 months</time_frame>
    <description>DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline to study completion, up to 12 months</time_frame>
    <description>TTR is defined as the duration from the start of treatment to the first onset of CR or PR in tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline to study completion, up to 12 months</time_frame>
    <description>DCR is defined as the proportions of patients achieving CR, PR, and stable disease (SD) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to study completion, up to 12 months</time_frame>
    <description>OS is defined as the duration from the start of treatment to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Baseline to 60 days after the last dose of study treatment</time_frame>
    <description>Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>MRG003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRG003</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>MRG003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to sign the ICF and follow the requirements specified in the protocol.&#xD;
&#xD;
          -  Age: ≥18 years，both genders.&#xD;
&#xD;
          -  Expected survival time≥6 months.&#xD;
&#xD;
          -  Patients with histologically confirmed advanced non-small cell lung cancer, and&#xD;
             without histologically confirmed small cell lung cancer (SCLC).&#xD;
&#xD;
          -  Positive EGFR expression in tumor specimen.&#xD;
&#xD;
          -  Failed in the prior second-line or above standard of care therapies.&#xD;
&#xD;
          -  Archival or biopsy tumor specimens should be provided.&#xD;
&#xD;
          -  Patients must have measurable lesions according to the Response Evaluation Criteria In&#xD;
             Solid Tumors (RECIST v1.1).&#xD;
&#xD;
          -  ECOG performance score 0 or 1.&#xD;
&#xD;
          -  AEs related to prior systemic chemotherapy and radical/extensive radiotherapy have&#xD;
             recovered to ≤ Grade 1 based on National Cancer Institute Common Terminology Criteria&#xD;
             for Adverse Events version 5.0 (NCI CTCAE V5.0).&#xD;
&#xD;
          -  No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) ≥ 50%.&#xD;
&#xD;
          -  Organ functions and coagulation function must meet the basic requirements.&#xD;
&#xD;
          -  Patients with childbearing potential must use effective contraception during the&#xD;
             treatment and for 6 months after the last dose of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any component of the investigational product.&#xD;
&#xD;
          -  No documented progression after prior treatment, or recurrence during or after prior&#xD;
             treatment.&#xD;
&#xD;
          -  Received radiotherapy, chemotherapy, biologicals, immunotherapy or other anti-tumor&#xD;
             drugs within 4 weeks prior to the first dose of study treatment.&#xD;
&#xD;
          -  Presence of central nervous system metastasis.&#xD;
&#xD;
          -  Patients with significant clinical symptoms such as pleural, abdominal or pericardial&#xD;
             effusion requiring puncture drainage prior to the first dose of study drug.&#xD;
&#xD;
          -  Any severe or uncontrolled systemic disease judged by the investigator.&#xD;
&#xD;
          -  Patients with poorly controlled heart diseases.&#xD;
&#xD;
          -  Evidence of active infections, including Hepatitis B, Hepatitis C or human&#xD;
             immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring&#xD;
             systemic therapy.&#xD;
&#xD;
          -  Prior history of other primary malignancies.&#xD;
&#xD;
          -  History of the following ophthalmologic abnormalities: severve dry eye syndrome;&#xD;
             keratoconjunctivitis sicca; severe exposure keratitis; any other condition that may&#xD;
             increase the risk of corneal epithelial damage.&#xD;
&#xD;
          -  History of severe skin disease requiring interruption of previous EGFR targeted&#xD;
             therapy; or chronic skin disease requiring oral or intravenous therapy.&#xD;
&#xD;
          -  History of interstitial lung disease (ILD) or pneumonitis, severe chronic obstructive&#xD;
             pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.&#xD;
&#xD;
          -  Pulmonary radiotherapy &gt; 30 Gy within 6 months prior to first dose of study drug.&#xD;
&#xD;
          -  Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Patients with active autoimmune disease or history of autoimmune disease, who are&#xD;
             using immunosuppressive agents or systemic hormone therapy and still receiving within&#xD;
             2 weeks prior to enrollment.&#xD;
&#xD;
          -  History of allogeneic tissue or solid organ transplant.&#xD;
&#xD;
          -  Female patients with a positive serum pregnancy test or who are breast feeding or do&#xD;
             not agree to take adequate contraceptive measures during the treatment and for 6&#xD;
             months after the last dose of study treatment.&#xD;
&#xD;
          -  Active uncontrolled concomitant diseases that might limit patient's compliance with&#xD;
             study requirements, or compromise patient's ability to provide written informed&#xD;
             consent.&#xD;
&#xD;
          -  Other conditions inappropriate for participation in this clinical trial, at the&#xD;
             discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Program Director, Master</last_name>
    <phone>86-21-61637960</phone>
    <email>clinicaltrials@miracogen.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, Doctor</last_name>
      <phone>86-10-87788701</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRG003</keyword>
  <keyword>Antibody Drug Conjugate (ADC)</keyword>
  <keyword>EGFR</keyword>
  <keyword>Non-Small Cell Lung Cancer (NSCLC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

